XNK Therapeutics AB nhasi yazivisa kuti murwere wekutanga akarapwa muChikamu chechipiri chekiriniki yekudzidza achishandisa XNK inotungamira autologous natural killer (NK) cell-based candidate drug musanganiswa neSanofi's anti-CD38 antibody Sarclisa (Isatuximab).
"Kuva nemurwere wekutanga kurapwa neNK masero muchidzidzo chekiriniki ichi chiitiko chakakosha mukuvandudzwa kwekiriniki yemutungamiri wedu wezvinodhaka," akadaro Johan Aschan, CMO weXNK Therapeutics. “Chidzidzo chacho chiri kufambira mberi zvakanaka, uye tinotarisira migumisiro yacho.”
Iyezvino muongorori-akatanga, akavhurika, asina kurongeka, akadzorwa, Chikamu chechipiri chidzidzo ISA-HC-NK (EudraCT: 2020-000994-26) inoenzanisa XNK inotungamira mumiriri mushonga wakasanganiswa neSanofi's anti-CD38 antibody Isatuximab neIsatuximab chete semushonga wekubatanidza unotevera. autologous stem cell transplantation mune varwere vachangobva kuongororwa akawanda myeloma. Chidzidzo chekiriniki chinoitika paKarolinska University Hospital panzvimbo yayo yeHuddinge uye inotenderedza huwandu hwevarwere makumi matanhatu nevarwere makumi matatu muruwoko rwega rwega rwekurapa.
ZVOKUBVA MUNYAYA INO:
- "Kuva nemurwere wekutanga kurapwa neNK masero muchidzidzo chekiriniki ichi chiitiko chakakosha mukuvandudzwa kwekiriniki yemutungamiri wedu wezvinodhaka,".
- Chidzidzo chekiriniki chinoitika paKarolinska University Hospital panzvimbo yayo yeHuddinge uye inotenderedza huwandu hwevarwere makumi matanhatu nevarwere makumi matatu muruwoko rwega rwega rwekurapa.
- XNK Therapeutics AB nhasi yazivisa kuti murwere wekutanga akarapwa muChikamu chechipiri chekiriniki yekudzidza achishandisa XNK inotungamira autologous natural killer (NK) cell-based candidate drug musanganiswa neSanofi's anti-CD38 antibody Sarclisa (Isatuximab).
